153 related articles for article (PubMed ID: 36719580)
1. Enhancing plant-derived smart nano inhibitor in targeting mammalian target of rapamycin (mTOR) in breast cancer using Curcuma longa-derived compound curcumin.
Alamri AH; Debnath S; Alqahtani T; Alqahtani A; Alshehri SA; Ghosh A
Environ Sci Pollut Res Int; 2023 Jan; ():. PubMed ID: 36719580
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnological synergy of mangiferin and curcumin in modulating PI3K/Akt/mTOR pathway: a novel front in ovarian cancer precision therapeutics.
Alharbi HM; Alqahtani T; Alamri AH; Kumarasamy V; Subramaniyan V; Babu KS
Front Pharmacol; 2023; 14():1276209. PubMed ID: 38239204
[No Abstract] [Full Text] [Related]
3. Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
Mol Divers; 2023 Jun; 27(3):1141-1162. PubMed ID: 35737256
[TBL] [Abstract][Full Text] [Related]
4. Natural Phytocompounds from Common Indian Spices for Identification of Three Potential Inhibitors of Breast Cancer: A Molecular Modelling Approach.
Hazra S; Ray AS; Rahaman CH
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235128
[TBL] [Abstract][Full Text] [Related]
5. Hitting the golden TORget: curcumin's effects on mTOR signaling.
Beevers CS; Zhou H; Huang S
Anticancer Agents Med Chem; 2013 Sep; 13(7):988-94. PubMed ID: 23272912
[TBL] [Abstract][Full Text] [Related]
6.
Feng L; Lu WH; Li QY; Zhang HY; Xu LR; Zang WQ; Guo WT; Li YF; Zheng WJ; Geng YX; Li Q; Liu YH
Am J Chin Med; 2023; 51(5):1189-1209. PubMed ID: 37314412
[TBL] [Abstract][Full Text] [Related]
7. In Silico and In Vitro Screening of 50 Curcumin Compounds as EGFR and NF-κB Inhibitors.
Saeed MEM; Yücer R; Dawood M; Hegazy MF; Drif A; Ooko E; Kadioglu O; Seo EJ; Kamounah FS; Titinchi SJ; Bachmeier B; Efferth T
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409325
[TBL] [Abstract][Full Text] [Related]
8. Curcumin's Beneficial Effects on Neuroblastoma: Mechanisms, Challenges, and Potential Solutions.
Zhai K; Brockmüller A; Kubatka P; Shakibaei M; Büsselberg D
Biomolecules; 2020 Oct; 10(11):. PubMed ID: 33105719
[TBL] [Abstract][Full Text] [Related]
9. Curcumin's Dose-Dependent Attenuation of Gastric Cancer Cell Progression Via the PI3K Pathway Blockade.
Xi G; Dong Q; Yang B; Jiao D; Khan S
Dose Response; 2023; 21(4):15593258231203585. PubMed ID: 37933268
[No Abstract] [Full Text] [Related]
10. Curcumin, its derivatives, and their nanoformulations: Revolutionizing cancer treatment.
Ahmad I; Ahmad S; Ahmad A; Zughaibi TA; Alhosin M; Tabrez S
Cell Biochem Funct; 2024 Jan; 42(1):e3911. PubMed ID: 38269517
[TBL] [Abstract][Full Text] [Related]
11. Exploring inhibitory potential of Curcumin against various cancer targets by in silico virtual screening.
Mahajanakatti AB; Murthy G; Sharma N; Skariyachan S
Interdiscip Sci; 2014 Mar; 6(1):13-24. PubMed ID: 24464700
[TBL] [Abstract][Full Text] [Related]
12. Curcumin disrupts the Mammalian target of rapamycin-raptor complex.
Beevers CS; Chen L; Liu L; Luo Y; Webster NJ; Huang S
Cancer Res; 2009 Feb; 69(3):1000-8. PubMed ID: 19176385
[TBL] [Abstract][Full Text] [Related]
13. Nano-curcumin's suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression.
Hosseini S; Chamani J; Hadipanah MR; Ebadpour N; Hojjati AS; Mohammadzadeh MH; Rahimi HR
Breast Cancer (Dove Med Press); 2019; 11():137-142. PubMed ID: 30936742
[TBL] [Abstract][Full Text] [Related]
14. Screening the possible anti-cancer constituents of Hibiscus rosa-sinensis flower to address mammalian target of rapamycin: an in silico molecular docking, HYDE scoring, dynamic studies, and pharmacokinetic prediction.
Rasul HO; Aziz BK; Ghafour DD; Kivrak A
Mol Divers; 2023 Oct; 27(5):2273-2296. PubMed ID: 36318405
[TBL] [Abstract][Full Text] [Related]
15. The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling.
Salucci S; Bavelloni A; Stella AB; Fabbri F; Vannini I; Piazzi M; Volkava K; Scotlandi K; Martinelli G; Faenza I; Blalock W
Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771452
[TBL] [Abstract][Full Text] [Related]
16. Curcuma as an adjuvant in colorectal cancer treatment.
Villegas C; Perez R; Sterner O; González-Chavarría I; Paz C
Life Sci; 2021 Dec; 286():120043. PubMed ID: 34637800
[TBL] [Abstract][Full Text] [Related]
17. Curcumin and Plumbagin Synergistically Target the PI3K/Akt/mTOR Pathway: A Prospective Role in Cancer Treatment.
Ahmad I; Hoque M; Alam SSM; Zughaibi TA; Tabrez S
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047624
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments.
Maiti P; Plemmons A; Dunbar GL
PLoS One; 2019; 14(12):e0225660. PubMed ID: 31841506
[TBL] [Abstract][Full Text] [Related]
19. Emerging Trends in Topical Delivery of Curcumin Through Lipid Nanocarriers: Effectiveness in Skin Disorders.
Waghule T; Gorantla S; Rapalli VK; Shah P; Dubey SK; Saha RN; Singhvi G
AAPS PharmSciTech; 2020 Oct; 21(7):284. PubMed ID: 33058071
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore-guided fragment-based design of novel mammalian target of rapamycin inhibitors: extra precision docking, fingerprint-based 2D and atom-based 3D-QSAR modelling.
Kumar A; Rai S; Rathi E; Agarwal P; Kini SG
J Biomol Struct Dyn; 2021 Mar; 39(4):1155-1173. PubMed ID: 32037974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
